Exciting news from China’s biopharma sector — the NMPA has conditionally approved Golixitinib Capsules (Gaoruizhe), developed by Dizal (Jiangsu) Pharmaceutical, for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) in adults.
Golixitinib is a selective JAK1 inhibitor that blocks the JAK/STAT pathway to suppress tumor cell proliferation, offering a new hope for patients battling this rare and aggressive cancer.
As China accelerates innovative drug approvals, companies like DengYue Medicine, a Hong Kong-based pharmaceutical wholesaler with a 30,000+ product portfolio covering innovative drugs, oncology, hematology, and orphan medicines, are helping bring these breakthroughs to global markets.
This milestone reflects not just regulatory progress, but the broader trend of China’s pharmaceutical industry evolving from “Made in China” to “Created in China.”
